NO20072601L - Azaindolkarboksamider - Google Patents
AzaindolkarboksamiderInfo
- Publication number
- NO20072601L NO20072601L NO20072601A NO20072601A NO20072601L NO 20072601 L NO20072601 L NO 20072601L NO 20072601 A NO20072601 A NO 20072601A NO 20072601 A NO20072601 A NO 20072601A NO 20072601 L NO20072601 L NO 20072601L
- Authority
- NO
- Norway
- Prior art keywords
- general formula
- azaindolkarboksamider
- ht1a
- compounds
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004054634A DE102004054634A1 (de) | 2004-11-12 | 2004-11-12 | Azaindolcarboxamide |
| PCT/EP2005/012127 WO2006050976A1 (de) | 2004-11-12 | 2005-11-11 | Azaindolcarboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20072601L true NO20072601L (no) | 2007-05-22 |
Family
ID=35929547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20072601A NO20072601L (no) | 2004-11-12 | 2007-05-22 | Azaindolkarboksamider |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070299091A1 (es) |
| EP (1) | EP1771448A1 (es) |
| JP (1) | JP2008519797A (es) |
| KR (1) | KR20070083843A (es) |
| CN (1) | CN101056878A (es) |
| AU (1) | AU2005303904A1 (es) |
| BR (1) | BRPI0517846A (es) |
| CA (1) | CA2575668A1 (es) |
| DE (1) | DE102004054634A1 (es) |
| EA (1) | EA200700909A1 (es) |
| IL (1) | IL180317A0 (es) |
| MX (1) | MX2007005649A (es) |
| NO (1) | NO20072601L (es) |
| WO (1) | WO2006050976A1 (es) |
| ZA (1) | ZA200700252B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10041479A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| EP1547592A1 (en) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
| DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
| WO2008153573A1 (en) * | 2007-06-15 | 2008-12-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | 4-phenylpiperazine derivatives with functionalized linkers as dopamine d3 receptor selective ligands and methods of use |
| KR20120124428A (ko) | 2009-12-30 | 2012-11-13 | 아르퀼 인코포레이티드 | 치환된 피롤로-아미노피리미딘 화합물 |
| CN105732639A (zh) | 2012-06-29 | 2016-07-06 | 辉瑞大药厂 | 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类 |
| CN105121439A (zh) | 2013-02-19 | 2015-12-02 | 辉瑞公司 | 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物 |
| EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| EP3172210B1 (en) | 2014-07-24 | 2020-01-15 | Pfizer Inc | Pyrazolopyrimidine compounds |
| KR102061952B1 (ko) | 2014-08-06 | 2020-01-02 | 화이자 인코포레이티드 | 이미다조피리다진 화합물 |
| WO2017024310A1 (en) | 2015-08-06 | 2017-02-09 | Chimerix, Inc. | Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents |
| AU2016322813B2 (en) | 2015-09-14 | 2021-04-01 | Pfizer Inc. | Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors |
| US11299476B2 (en) | 2016-03-14 | 2022-04-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof |
| US10870660B2 (en) | 2016-07-28 | 2020-12-22 | Shionogi & Co., Ltd. | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect |
| CN106279071B (zh) * | 2016-08-10 | 2019-01-04 | 广东东阳光药业有限公司 | 苯基哌嗪衍生物及其使用方法和用途 |
| WO2019060692A1 (en) | 2017-09-21 | 2019-03-28 | Chimerix, Inc. | MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES |
| WO2019146740A1 (ja) | 2018-01-26 | 2019-08-01 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する環式化合物 |
| EP3744721A4 (en) | 2018-01-26 | 2021-11-10 | Shionogi & Co., Ltd | CONDENSED CYCLIC COMPOUND WITH ANTAGONISM TO DOPAMINE D3 RECEPTOR |
| AU2019340675A1 (en) | 2018-09-11 | 2021-03-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340113C (en) * | 1988-05-24 | 1998-11-03 | Magid A. Abou-Gharbia | Aryl-and heteroaryl piperazinyl carboxamides having central nervous system activity |
| ES2027898A6 (es) * | 1991-01-24 | 1992-06-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados de la 2-metoxifenilpiperacina. |
| PL310443A1 (en) * | 1993-03-01 | 1995-12-11 | Merck Sharp & Dohme | Derivatives of pyrolo-pyridine |
| HUP0103987A3 (en) * | 2001-09-28 | 2004-11-29 | Richter Gedeon Vegyeszet | Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates |
| CN1665503A (zh) * | 2002-07-04 | 2005-09-07 | 施瓦茨制药有限公司 | 杂芳烃甲酰胺作为多巴胺－d3配体用于治疗中枢神经系统疾病的用途 |
| WO2004024878A2 (en) * | 2002-09-14 | 2004-03-25 | Gov't Of The U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services | Structurally rigid dopamine d3 receptor selective ligands and process for making them |
| JP2004123562A (ja) * | 2002-09-30 | 2004-04-22 | Japan Science & Technology Corp | 神経細胞死抑制作用を有する化合物を用いた医薬 |
| JP2006528702A (ja) * | 2003-05-21 | 2006-12-21 | プロシディオン・リミテッド | グリコーゲンホスホリラーゼのピロロピリジン−２−カルボン酸アミドインヒビター |
| SE0401655D0 (sv) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | New compounds |
-
2004
- 2004-11-12 DE DE102004054634A patent/DE102004054634A1/de not_active Ceased
-
2005
- 2005-11-11 BR BRPI0517846-0A patent/BRPI0517846A/pt not_active IP Right Cessation
- 2005-11-11 CN CNA2005800387992A patent/CN101056878A/zh active Pending
- 2005-11-11 CA CA002575668A patent/CA2575668A1/en not_active Abandoned
- 2005-11-11 KR KR1020077009695A patent/KR20070083843A/ko not_active Application Discontinuation
- 2005-11-11 EP EP05805690A patent/EP1771448A1/de not_active Withdrawn
- 2005-11-11 US US11/667,601 patent/US20070299091A1/en not_active Abandoned
- 2005-11-11 EA EA200700909A patent/EA200700909A1/ru unknown
- 2005-11-11 AU AU2005303904A patent/AU2005303904A1/en not_active Abandoned
- 2005-11-11 WO PCT/EP2005/012127 patent/WO2006050976A1/de active Application Filing
- 2005-11-11 MX MX2007005649A patent/MX2007005649A/es not_active Application Discontinuation
- 2005-11-11 JP JP2007540597A patent/JP2008519797A/ja active Pending
-
2006
- 2006-12-25 IL IL180317A patent/IL180317A0/en unknown
-
2007
- 2007-01-09 ZA ZA200700252A patent/ZA200700252B/xx unknown
- 2007-05-22 NO NO20072601A patent/NO20072601L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007005649A (es) | 2007-07-09 |
| EA200700909A1 (ru) | 2007-12-28 |
| ZA200700252B (en) | 2009-05-27 |
| CN101056878A (zh) | 2007-10-17 |
| AU2005303904A1 (en) | 2006-05-18 |
| KR20070083843A (ko) | 2007-08-24 |
| CA2575668A1 (en) | 2006-05-18 |
| IL180317A0 (en) | 2007-06-03 |
| BRPI0517846A (pt) | 2008-10-21 |
| WO2006050976A1 (de) | 2006-05-18 |
| US20070299091A1 (en) | 2007-12-27 |
| DE102004054634A1 (de) | 2006-05-18 |
| EP1771448A1 (de) | 2007-04-11 |
| JP2008519797A (ja) | 2008-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20072601L (no) | Azaindolkarboksamider | |
| DK2023918T3 (da) | Cyclosporiner til behandlingen og forebyggelse af okulære lidelser | |
| NO20073831L (no) | Medikamenter for behandling eller forebygging av fibrotiske sykdommer | |
| NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
| NO20064201L (no) | Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling | |
| NO20060981L (no) | Pyridazinderivater og deres anvendelse som terapeutiske midler | |
| NO20084328L (no) | Nye forbindelser | |
| ATE509917T1 (de) | Gamma-secretase-inhibitoren | |
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| HUP0301513A2 (hu) | O-Aril-glükozid SGLT2 inhibitorok és eljárás elżállításukra | |
| NO20062704L (no) | Azabicykliske heterocykler som cannabinoide reseptormodulatorer | |
| NO20082594L (no) | Pyrimidinylbenzotiofenforbindelser | |
| WO2005013892A3 (en) | Hydrolytically-resistant boron-containing therapeutics and methods of use | |
| NO20055421L (no) | Kinolinderivater som fosfodiestrase-inhibitorer | |
| ATE537175T1 (de) | Neue piperazino-dihydrothienopyrimidin-derivate | |
| MY148480A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| NO20076059L (no) | 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer | |
| NO20092286L (no) | Nitrogenhaldige heterosykliske forbindelser og anvendelse derav | |
| NO20085100L (no) | Nye forbindelser | |
| NO20073416L (no) | Indoler nyttig i behandlingen av inflammasjon | |
| NO20081942L (no) | Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser | |
| NO20081804L (no) | Pyrazolforbindelser egnet til behandling av inflammasjon | |
| NO20076357L (no) | Azabicykliske heterocykler som cannabinoid reseptor modulatorer | |
| NO20081888L (no) | Triazolforbindelser som lipoksygenaseinhibitorer | |
| NO20083058L (no) | Cykloheksylsulfonamidderivater med H3 reseptor aktivitet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |